Bioventus will soon have a new chief executive officer.
Anthony Bihl, a former executive at Bayer Healthcare, Siemens Medical Solutions Diagnostics and American Medical Systems, will take over as CEO at Biologics as of Dec. 2, the Durham-based company said Thursday.
Bioventus focuses on orthopedic healing technologies.
“Tony’s strategic aptitude, coupled with his proven track record of producing extraordinary results, made him the perfect choice to lead Bioventus,” said Marty Sutter, managing director of Essex Woodlands, a healthcare growth equity firm that is the lead investor in Bioventus. “We’re pleased to have him join the company and are confident he will help propel Bioventus to even greater success.”
The addition of Bihl is one of several changes made at the company this year. Alessandra Pavesio recently was named the company’s chief science officer. A chief medical officer wsas named earlier.
Bioventus launched in 2012 as a spinoff from medical device firm Smith & Nephew.
“I’m excited for the opportunity to lead Bioventus, a company on the verge of establishing itself as a global biologics leader,” Bihl said in a statement. “Although the current healthcare environment is challenging for many companies, Bioventus is in the unique position of leveraging what it has today – proven, market-leading offerings – while aggressively planning for the future, through its development projects and product acquisition strategy. I look forward to working with the Bioventus leadership team to capitalize on these opportunities.”
Bihl, 57, most recently was CEO at American Medical Systems which was acquired by Endo Pharmaceuticals in 2011.
He also was CEO of the Siemens group and was president of the Bayer Healthcare group.
Mark Augusti had been CEO at Bioventus.
